Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody-drug conjugates: Case reports and management strategies. | Sci Prog | 2025 | 40734391 | PubTator, text mining | PubMed |
| Recent advances in theranostics and oncology PET: emerging radionuclides and targets. | Ann Nucl Med | 2025 | 40717183 | PubTator, text mining | PubMed |
| Unlocking the potential of antibody-drug conjugates in cervical cancer: emerging targets and clinical trials. | Front Pharmacol | 2025 | 40697656 | PubTator, text mining | PubMed |
| TROP2-targeted molecular imaging: a promising tool for precision oncology. | Am J Nucl Med Mol Imaging | 2025 | 40688535 | PubTator, text mining | PubMed |
| Trop2-targeted immunoPET ligands. | Am J Nucl Med Mol Imaging | 2025 | 40688534 | PubTator, text mining | PubMed |
| [89Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer. | Am J Nucl Med Mol Imaging | 2025 | 40688533 | PubTator, text mining | PubMed |
| Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models. | Int J Gynecol Cancer | 2025 | 40680453 | PubTator, text mining | PubMed |
Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies. | JCO Precis Oncol | 2025 | 40669019 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial. | Clin Transl Sci | 2025 | 40657894 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology. | Int J Mol Sci | 2025 | 40650299 | PubTator, text mining | PubMed |
| Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer. | Exp Hematol Oncol | 2025 | 40646627 | PubTator, text mining | PubMed |
| The role of radiotheranostics in personalized treatment for breast cancer. | Med Oncol | 2025 | 40643742 | PubTator, text mining | PubMed |
| The C-terminus of the tail fiber protein of PB1-like phages is responsible for the host recognition. | Virus Genes | 2025 | 40637811 | PubTator, text mining | PubMed |
| TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications. | J Oral Pathol Med | 2025 | 40624990 | PubTator, text mining | PubMed |
| A meta-analysis and systematic review of the first Trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer. | Eur J Clin Pharmacol | 2025 | 40624355 | PubTator, text mining | PubMed |
| Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. | Sci Rep | 2025 | 40615466 | PubTator, text mining | PubMed |
| [Antibody-drug conjugates in breast cancer: Resistance mechanisms and prospects]. | Bull Cancer | 2025 | 40615323 | PubTator, text mining | PubMed |
| Multicheckpoint Cellular Targeting of siRNAs Using Antibody-Directed Lipid-Polymer Hybrid Nanoparticles. | Bioconjug Chem | 2025 | 40609116 | PubTator, text mining | PubMed |
| Proline-Mediated Enhancement in Evolvability of Disulfide-Rich Peptides for Discovering Protein Binders. | J Am Chem Soc | 2025 | 40601296 | PubTator, text mining | PubMed |
| The prognostic and therapeutic potential of Claudin-6 and Trop-2 expression as targeted biomarkers in serous ovarian cancer: An observational study. | Medicine (Baltimore) | 2025 | 40587664 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=27